Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference
11:00am, Wednesday, 08'th Apr 2020
STAMFORD, Conn., April 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed.
Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference
11:00am, Wednesday, 08'th Apr 2020
STAMFORD, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...
-$0.64 EPS Expected for Cara Therapeutics Inc (NASDAQ:CARA) This Quarter
09:48am, Monday, 06'th Apr 2020
Brokerages expect Cara Therapeutics Inc (NASDAQ:CARA) to post ($0.64) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates fo
Cubist Systematic Strategies LLC Has $938,000 Holdings in Cara Therapeutics Inc (NASDAQ:CARA)
09:00am, Monday, 06'th Apr 2020
Cubist Systematic Strategies LLC increased its holdings in Cara Therapeutics Inc (NASDAQ:CARA) by 358.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exch
Cara Therapeutics Inc (NASDAQ:CARA) Shares Sold by Advisor Group Inc.
08:04am, Sunday, 05'th Apr 2020
Advisor Group Inc. reduced its position in Cara Therapeutics Inc (NASDAQ:CARA) by 41.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm
Cara Therapeutics Inc (NASDAQ:CARA) Expected to Announce Quarterly Sales of $4.83 Million
06:54am, Sunday, 05'th Apr 2020
Equities research analysts predict that Cara Therapeutics Inc (NASDAQ:CARA) will announce $4.83 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued e
Cara Therapeutics (NASDAQ:CARA) Shares Up 5.2%
07:32am, Tuesday, 31'st Mar 2020
Cara Therapeutics Inc (NASDAQ:CARA) shot up 5.2% during trading on Monday . The stock traded as high as $13.38 and last traded at $13.26, 370,140 shares traded hands during mid-day trading. A decline
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2019
11:25pm, Monday, 30'th Mar 2020
Corporate Highlights
Cannabis Stock Gainers And Losers From March 30, 2020
08:37pm, Monday, 30'th Mar 2020
Gainers
VIVO Cannabis (OTC: VVCIF) stocks closed up 23.57% at $0.18
Meridian Bioscience (NASDAQ:) stocks closed up 13.37% at $7.97
The Flowr (OTC: FLWPF) stocks...
Piper Sandler Comments on Cara Therapeutics Inc's FY2022 Earnings (NASDAQ:CARA)
07:38am, Monday, 30'th Mar 2020
Cara Therapeutics Inc (NASDAQ:CARA) – Equities research analysts at Piper Sandler cut their FY2022 earnings per share estimates for shares of Cara Therapeutics in a report released on Wednesday, Mar
Blueshift Asset Management LLC Makes New Investment in Cara Therapeutics Inc (NASDAQ:CARA)
10:08am, Sunday, 29'th Mar 2020
Blueshift Asset Management LLC bought a new position in shares of Cara Therapeutics Inc (NASDAQ:CARA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Co
Cara Therapeutics (NASDAQ:CARA) Upgraded at BidaskClub
06:42am, Friday, 27'th Mar 2020
Cara Therapeutics (NASDAQ:CARA) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, BidAskClu
Covid-19-related activity - healthcare
11:37am, Wednesday, 25'th Mar 2020
Cara Therapeutics (NASDAQ:CARA): despite Covid-19 disruptions, remains on track to report topline data from the Phase 3 KALM-2 study of Korsuva (difelikefalin) in hemodialysis patients with moderate-t
Cara Therapeutics plans to sumbit NDA for KORSUVA injection in 2H20 CARA
11:25am, Wednesday, 25'th Mar 2020
Cara Therapeutics plans to sumbit NDA for KORSUVA injection in 2H20 CARA
Cara Therapeutics expects interim analysis from Phase 2 trial in AD in Q2 CARA
11:25am, Wednesday, 25'th Mar 2020
Cara Therapeutics expects interim analysis from Phase 2 trial in AD in Q2 CARA
